SPYVLP102

**SPYVLP102** is SpyBiotech's lead virus-like particle (VLP) vaccine candidate targeting human cytomegalovirus (HCMV), a betaherpesvirus causing congenital infections and birth defects. It utilizes the company's proprietary SpyTag/SpyCatcher protein "superglue" technology to covalently attach HCMV glycoprotein antigens (e.g., gB, pentamer complex) to VLPs, enhancing immune response potency, breadth, and durability compared to traditional vaccines. Developed for prophylactic use in seronegative women of childbearing age, it is advancing through preclinical optimization with partnerships like Selexis for cell line development to support clinical manufacturing.[1][12][13]